Key Highlights
- Novartis' pelacarsen drug lowered harmful Lp(a) cholesterol but failed to significantly improve cardiovascular outcomes in a late-stage trial involving more than 8,000 patients.
- Shares of Amgen fell about 5% and Ionis Pharmaceuticals sank 10% in extended trading following the announcement, while Novartis stock fell 3%.
- Analysts had modeled peak annual sales of $4 billion to $5 billion for pelacarsen alone, underscoring the scale of the broader Lp(a) treatment market at stake.
- Amgen's competing drug faces the clearest direct read-through from the failure, while Eli Lilly's medicine is being tested in a broader, less comparable patient population.
A First Major Setback in the Race to Treat Lp(a)
Novartis' failure in a closely watched cardiovascular trial has raised questions over one of the pharmaceutical industry's biggest drug races and rival treatments from Amgen and Eli Lilly. The pelacarsen drug, developed jointly with Ionis Pharmaceuticals, reduced a particularly harmful form of cholesterol known as Lp(a) in a late-stage trial but failed to significantly improve cardiovascular outcomes, Novartis said after markets closed on Friday.
It marks the first major clinical setback in the race to develop treatments targeting Lp(a), which elevates cardiovascular risk in roughly one in five people worldwide and for which there is currently no approved targeted treatment. Although Amgen and Lilly are testing different technologies that have shown deeper reductions in Lp(a) than pelacarsen achieved, analysts say the failure raises risk across a market expected to be worth billions of dollars.
“Weakened, but Not Disproven”
Analysts at Citi said in a research note that the Lp(a) hypothesis has been weakened but not disproven, noting that details remain scarce beyond the topline miss, including the magnitude by which pelacarsen lowered Lp(a) levels. They said more data is needed to determine whether the miss reflects the drug's specific mechanism, the trial's design, or a more fundamental challenge to the hypothesis that lowering Lp(a) reduces heart attacks and strokes.
Novartis said full results will be presented at an upcoming medical congress. The company's chief medical officer said the data provide important evidence advancing scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes, and may help inform future approaches to cardiovascular risk management.
A Costly Blow Amid a Steep Patent Cliff
Lp(a), discovered in 1963, contributes to plaque buildup in arteries and blood clotting, and a person's levels are determined almost entirely by genetics rather than lifestyle factors. Analysts had modeled peak annual sales of $4 billion to $5 billion for pelacarsen alone if the drug had succeeded. The failure adds pressure on Novartis as it faces what its chief executive has called the steepest patent cliff in company history, with its bestselling heart drug Entresto having already lost key patent protections.
Novartis emphasized that the more than 8,000 patients in the trial were already receiving optimized standard care, while analysts at Jefferies noted that improving standards of care generally are making it harder and more costly for experimental drugs to demonstrate added benefit in clinical trials.
Ripple Effects Across the Sector
Shares of Amgen fell about 5% in extended trading following the news, while Ionis Pharmaceuticals sank 10%. Analysts at Citi said the first dedicated outcomes failure in the class lowers confidence broadly and places greater pressure on later-stage studies to demonstrate a clinically meaningful reduction in major cardiovascular events. Amgen's competing drug, olpasiran, faces the clearest direct read-through from Novartis' failure, while Lilly's medicine is being tested in a broader patient population that includes some without established cardiovascular disease, potentially limiting how directly the results apply. Analysts noted Lilly's drug is also less material to the company's overall valuation than pelacarsen was for Novartis.
Shares of NewAmsterdam Pharma, which is also developing a treatment to lower cardiovascular risk through Lp(a) reduction, fell 12% in extended trading.
Can Other Approaches Still Succeed?
Because rival drugs use different mechanisms to lower Lp(a), some may prove more effective than pelacarsen, according to analysts at William Blair, who said that could give drugmakers reason to continue developing treatments, particularly for patients starting with very high Lp(a) levels. They noted meaningful risk to future Lp(a)-driven cardiovascular trials in light of Novartis' results, even as the broader scientific question remains open.






Please wait processing your request...